<TEI xmlns="http://www.tei-c.org/ns/1.0"><text><body><listBibl><biblFull><editionStmt><edition><date type="whenDownloaded">2017-08-22</date><date type="whenCreated">2017-12-01</date></edition></editionStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Molecular mechanism underlying the impact of vitamin D on diseaseactivity of MS</title><author role="aut"><persName><forename type="first">Kassandra L.</forename><forename type="initial">KL</forename><surname>Munger</surname></persName><affiliation type="rp">Dept Nutr, Bldg 2,3rd Floor,665 Huntington Ave, Boston, MA 02115 USA</affiliation><affiliation>Harvard Sch Publ Hlth, Boston, MA USA</affiliation></author><author role="aut"><persName><forename type="first">Karl</forename><forename type="initial">K</forename><surname>Koechert</surname></persName><affiliation>Bayer HealthCare, Berlin, Germany</affiliation></author><author role="aut"><persName><forename type="first">Kelly C.</forename><forename type="initial">KC</forename><surname>Simon</surname></persName><affiliation>Harvard Sch Publ Hlth, Boston, MA USA</affiliation></author><author role="aut"><persName><forename type="first">Ludwig</forename><forename type="initial">L</forename><surname>Kappos</surname></persName><affiliation>Univ Basel Hosp, Basel, Switzerland</affiliation></author><author role="aut"><persName><forename type="first">Chris H.</forename><forename type="initial">CH</forename><surname>Polman</surname></persName><affiliation>Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands</affiliation></author><author role="aut"><persName><forename type="first">Mark S.</forename><forename type="initial">MS</forename><surname>Freedman</surname></persName><affiliation>Ottawa Hosp, Res Inst, Ottawa, ON, Canada</affiliation></author><author role="aut"><persName><forename type="first">Hans P.</forename><forename type="initial">HP</forename><surname>Hartung</surname></persName><affiliation>Heinrich Heine Univ, Dusseldorf, Germany</affiliation></author><author role="aut"><persName><forename type="first">David H.</forename><forename type="initial">DH</forename><surname>Miller</surname></persName><affiliation>UCL Inst Neurol, London, England</affiliation></author><author role="aut"><persName><forename type="first">Xavier</forename><forename type="initial">X</forename><surname>Montalban</surname></persName><affiliation>Hosp Univ Vall dHebron, Barcelona, Spain</affiliation><idno type="orcid">Montalban Gairin, Xavier/0000-0002-0098-9918</idno></author><author role="aut"><persName><forename type="first">Gilles</forename><forename type="initial">G</forename><surname>Edan</surname></persName><affiliation>Hop Pontchaillou, CHU, Rennes, France</affiliation></author><author role="aut"><persName><forename type="first">Frederik</forename><forename type="initial">F</forename><surname>Barkhof</surname></persName><affiliation>Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands</affiliation></author><author role="aut"><persName><forename type="first">Dirk</forename><forename type="initial">D</forename><surname>Pleimes</surname></persName><affiliation>Bayer HealthCare, Berlin, Germany</affiliation></author><author role="aut"><persName><forename type="first">Rupert</forename><forename type="initial">R</forename><surname>Sandbrink</surname></persName><affiliation>Bayer HealthCare, Berlin, Germany</affiliation><affiliation>Heinrich Heine Univ, Dusseldorf, Germany</affiliation></author><author role="aut"><persName><forename type="first">Alberto</forename><forename type="initial">A</forename><surname>Ascherio</surname></persName><affiliation>Harvard Sch Publ Hlth, Boston, MA USA</affiliation></author><author role="aut"><persName><forename type="first">Christoph</forename><forename type="initial">C</forename><surname>Pohl</surname></persName><affiliation>Bayer HealthCare, Berlin, Germany</affiliation><affiliation>Univ Hosp Bonn, Dept Neurol, Bonn, Germany</affiliation></author></analytic><monogr><title level="j">ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY</title><title level="j" type="abbrevIso">Ann. Clin. Transl. Neurol</title><idno type="issn">2328-9503</idno><idno type="lissn">2328-9503</idno><imprint><publisher>WILEY-BLACKWELL</publisher><pubPlace>HOBOKEN</pubPlace><date type="yearPub">2014</date><date type="datePub">2014</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="pp">605-617</biblScope><biblScope unit="pagesNo">13</biblScope></imprint></monogr><idno type="doi">10.1002/acn3.91</idno><idno type="pubmed">25285313</idno><idno type="utKey">000209815300008</idno></biblStruct></sourceDesc><profileDesc><langUsage><language xml:lang="en">English</language></langUsage><textClass><classCode scheme="wos">Clinical Neurology</classCode><classCode scheme="wos">Neurosciences</classCode><classCode scheme="typology">Article</classCode></textClass><abstract xml:lang="en">Objective: Some previous studies suggest modest to strong effects of 25-hydroxyvitamin D(25(OH)D) on multiple sclerosis (MS) activity. The objective of this study was to explore the mechanistic rationale that may explain potential clinical effects of 25(OH) D. Methods: This study measured serum 25(OH) D levels and global gene expression profiles over a course of up to 2 years in patients starting treatment with interferon beta-1b (IFNB-1b) after a clinically isolated syndrome. MS disease activity was assessed by the number of gadolinium-enhancing lesions present on repeated magnetic resonance imaging (MRIs). Results: The number of gadolinium-enhancing lesions was highly significantly associated with 25(OH) D levels. Conducting various systems-level analyses on the molecular level, multiple lines of evidence indicated that 25 (OH) D regulates expression dynamics of a large gene-gene interaction system which primarily regulates immune modulatory processes modulating MS activity. The vitamin D response element was significantly enriched in this system, indicating a direct regulation of this gene interaction network through the vitamin D receptor. With increasing 25(OH) D levels, resulting regulation of this system was associated with a decrease in MS activity. Within the complex network of genes that are regulated by 25(OH) D, well-described targets of IFNB-1b and a regulator of sphingosine-1-phosphate bioavailability were found. The 25(OH) D effects on MS activity were additively enhanced by IFNB-1b. Interpretation: Here, we provide mechanistic evidence that an unbalanced 25(OH) D gene expression system may affect MS activity. Our findings support a potential benefit of monitoring and managing vitamin D levels (e.g., through supplementation) in early MS patients treated with IFN-beta-1b</abstract></profileDesc></biblFull></listBibl></body></text></TEI>
